Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
复制标题
DOI:
10.3390/jcm9113655
复制
发表时间:
2020-11-13
影响因子:
3.9
通讯作者:
Strosberg J
中科院分区:
文献类型:
--
作者:
Cives M;Pelle' E;Strosberg J
Treatment options for neuroendocrine tumors (NETs) and carcinomas (NECs) are expanding. Early-phase studies have shown preliminary evidence of the antitumor activity of alpha-emitting peptide receptor radionuclide therapy (PRRT), and novel radiopeptides incorporating somatostatin receptor antagonists (rather than agonists) have been developed. Several tyrosine kinase inhibitors (TKIs) with antiangiogenic potential have been evaluated in patients with NETs, including lenvatinib, axitinib, cabozantinib and pazopanib. Recently, two phase 3 clinical trials have demonstrated the efficacy and safety of surufatinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, fibroblast growth factor receptor (FGFR)-1 and colony stimulating factor-1 receptor (CSF-1R), in patients with pancreatic and extra-pancreatic NETs. Multiple clinical trials of combination immunotherapy have been recently completed, but interpretation of the results is hampered by small samples sizes and discordant outcomes. This review summarizes recent data on emerging treatments for neuroendocrine neoplasms.
登录
查看更多内容
影响因子:
6.2
作者:
Mehnert, Janice M.;Bergsland, Emily;Piha-Paul, Sarina A.
通讯作者:
Piha-Paul, Sarina A.
影响因子:
4.1
作者:
Cives, Mauro;Pelle', Eleonora;Silvestris, Franco
通讯作者:
Silvestris, Franco
影响因子:
11.5
作者:
Klein, Oliver;Kee, Damien;Cebon, Jonathan
通讯作者:
Cebon, Jonathan
影响因子:
4.1
作者:
Navalkissoor, Shaunak;Grossman, Ashley
通讯作者:
Grossman, Ashley
影响因子:
2.8
作者:
Chatterjee N;Walker GC
通讯作者:
Walker GC